CPSI

Analyst Note: CPSI (Computer Programs and Systems, Inc.)

Date: 2026-06-13 Current Price: $9.19

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: N/A (Structure is in place, but price has not fired the breakout signal) Breakout Level: Not yet fired. Current Price: $9.19 Extension: N/A (Price is not currently extended above a breakout level).

2. Thesis Layer

This is a TACTICAL, setup-led name. There is NO named secular thesis attached to this specific setup at this date. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals provided in the recent earnings data. No macro or thematic thesis should be invented to support the position; the conviction rests on the convergence of management's operational improvements and the structural price formation.

3. The Business

Company Overview: CPSI is a healthcare technology firm founded in 1979 and based in Mobile, Alabama. The company specializes in delivering comprehensive IT solutions and services to community hospitals, physician clinics, skilled nursing facilities, and assisted living centers.

Core Offerings:

• Patient Management: Software facilitating patient identification and information capture throughout the healthcare delivery process.
• Financial Accounting: Business office applications for tracking and coordinating data for managerial decision-making.
• Clinical Software: Automation of record-keeping and reporting for laboratory, radiology, physical therapy, respiratory care, and pharmacy.
• Integration: The "Centriq" interface centralizes patient data from multiple care areas.
• Post-Acute Care: Specialized solutions for data-driven clinical and financial improvements in post-acute settings.
• Services: Extensive support including software application support, hardware maintenance, educational programs, revenue cycle management (RCM), strategic consulting, and managed IT services.

Recent Operational Performance (Source: Earnings Transcript, 2026-04-01):

• Pipeline Strength: The dollar value of the overall sales pipeline is at a 9-quarter high, having increased 53% since the beginning of Q3.
• Recurring Revenue Mix: Recurring deals now represent >70% of the pipeline, a significant improvement from approximately 57% the previous summer.
• Encoder Growth: The encoder pipeline grew 74%, driven by new business and channel partners.
• Bookings: Q4 bookings totaled $19.8 million (Total Contract Value), up from $15.5 million sequentially and $14.3 million year-over-year.
• Financial Health Revenue: Generated $56.2 million, representing 65% of total company revenue (up 2% YoY), primarily driven by the Encoder business.
• Strategic Wins: Selected by SAIC as the preferred partner for EHR and RCM technology in rural healthcare alliances.
• Margin Expansion: Adjusted EBITDA for the quarter was $19.2 million, with margins expanding 160 basis points from 20.4% in Q4 2024 to 22% in the current quarter.

Management Expectations: Management expects to achieve modest revenue growth in 2026 and anticipates approximately 200 basis points of improvement in adjusted EBITDA margins for the full year.

4. Archetype and Conviction

Archetype: Growth Leader Fit: The company fits the Growth Leader archetype due to the accelerating pipeline growth (53% increase), the shift toward higher-margin recurring revenue (70% of pipeline), and the demonstrated margin expansion (160 bps in one quarter). The business model is shifting from one-time projects to a more stable, recurring SaaS-like revenue stream, supported by strategic partnerships (Microsoft, SAIC).

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and setup-led, lacking a broad secular macro tailwind, but the internal business momentum is strong.
• Evidence Quality: High. The evidence is recent (April 2026) and specific, citing concrete figures for pipeline, bookings, and margins.
• Structural Quality: Moderate. The setup is "Forming," meaning the structural quality is present but unconfirmed. The high ATR (5.9%) suggests the market is actively pricing in the volatility associated with this growth.
• Setup Readiness: Partial. The coil is forming, which is a positive signal but not a confirmed entry. The price must break out to confirm the setup.
• Rerating Potential: High. The combination of margin expansion (22% EBITDA margin) and a shift to recurring revenue could support a multiple expansion if the breakout occurs.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued expansion of the recurring revenue mix beyond 70%.
• Confirmation of the 200 basis points of EBITDA margin improvement in the next quarter.

What Would Invalidate the Case:

• A significant contraction in the sales pipeline or a reversal in the recurring revenue mix.

Gaps in Evidence:

• Breakout ATR: The ATR at the moment of breakout is not yet recorded, as the breakout has not occurred.
• Valuation Context: No specific P/E or EV/EBITDA multiples are provided in the evidence block to contextualize the $9.19 price against historical or peer valuations.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Pipeline value at 9-quarter high with 53% sequential increase; Recurring deals now >70% of pipeline; Adjusted EBITDA margin expanded 160 bps to 22% in Q4 2026. Key risks: Setup is in "Forming" state with no confirmed breakout; High current ATR (5.9%) indicates elevated volatility; Tactical setup lacks a named secular thesis to provide macro tailwinds. Sizing hint: Position size should be conservative relative to a confirmed breakout, reflecting the partial readiness of the coil structure. Expected path: Management expects modest revenue growth and 200 bps margin improvement in 2026; structural implications suggest a potential rerating if the forming coil resolves to the upside. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.